Want to see IMCR full AI Analyst Report?
Top Page
Immunocore Holdings
(NASDAQ:IMCR)
Select Model
Select Model
Rating:61Neutral
Price Target:
$31.00
▼(-1.43% Downside)
Action:Reiterated
Date:05/28/26
The score is driven primarily by solid top-line growth and strong gross profitability alongside a currently conservative balance sheet, offset by ongoing net losses and negative TTM operating/free cash flow. Technicals are neutral-to-soft versus longer-term moving averages, and valuation reflects a growth premium with no dividend support; corporate events add a small governance-stability positive.
Positive Factors
Commercial product + platform
Having an approved, revenue-generating therapy (KIMMTRAK) plus a proprietary ImmTAX TCR platform provides durable structural advantages: an established commercial engine to fund operations and a scalable R&D platform that can generate multiple pipeline assets and long-term revenue diversification.
Negative Factors
Negative operating/free cash flow
Sustained negative operating and free cash flow indicate ongoing cash burn from R&D and commercialization. This elevates reliance on external financing or partnerships, increases dilution and execution risk, and limits the company's ability to self-fund growth until cash flow turns reliably positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial product + platform
Having an approved, revenue-generating therapy (KIMMTRAK) plus a proprietary ImmTAX TCR platform provides durable structural advantages: an established commercial engine to fund operations and a scalable R&D platform that can generate multiple pipeline assets and long-term revenue diversification.
Read all positive factors
Immunocore Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Immunocore Holdings is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Immunocore Holdings is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyImmunocore Holdings (IMCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.57B
Dividend YieldN/A
Average Volume (3M)394.33K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth23.64%
EPS Growth-29.23%
CountryUS
Employees493
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding50,865,574
10 Day Avg. Volume405,035
30 Day Avg. Volume394,330
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue3.72
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda229.83
Forecast
1Y Price Target
$69.71Price Target Upside121.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.12
Revenue Forecast (FY)$447.95M
Immunocore Holdings Business Overview & Revenue Model
Company Description
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of ...
How the Company Makes Money
Immunocore primarily makes money through (1) product revenue from sales of its commercial therapy, KIMMTRAK (tebentafusp), where revenue is generated when the drug is sold to customers (typically wholesalers/specialty distributors and healthcare c...
Immunocore Holdings Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial execution for KIMTRAK (29% YoY revenue growth to $400M), broad global adoption (39 approvals, 30 launches), meaningful real-world survival and duration signals, a diversified pipeline anchored by three Phase 3 trials with near-term readouts, and a solid cash position (~$864M). Balanced against this are expected revenue-growth moderation in 2026, rising R&D investment, event-driven timing uncertainty for key OS trials, small early-stage cohorts (HIV), and competitive/operational risks tied to trial geography and evolving treatment options. Overall, the company presents momentum and optionality but with important clinical and timing risks that will be clarified by upcoming data readouts.Positive Updates
Strong KIMTRAK Revenue Growth
Net revenue of $400,000,000 for 2025, representing a 29% year-over-year increase versus 2024 (underlying growth ~20% when normalized for rebate reserves).
Negative Updates
Expected Moderation of Revenue Growth in 2026
Management expects growth to moderate as KIMTRAK enters its fifth year on the market; recent sequential quarterly revenue growth was in the 4%–7% range and is expected to slow further in 2026.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong KIMTRAK Revenue Growth
Net revenue of $400,000,000 for 2025, representing a 29% year-over-year increase versus 2024 (underlying growth ~20% when normalized for rebate reserves).
Read all positive updates
Company Guidance
Management guided that KIMTRAK generated $400 million in 2025 net revenue (up >29% YoY; underlying ~20% when normalizing rebate reserves), is approved in 39 countries and launched in 30 markets, serves roughly 1,000 patients/year, and has a real‑world mean duration of therapy of 14 months with a 150‑patient RWE median overall survival of 28 months (one in four patients alive at 3 years); commercial penetration exceeds 70% across major markets, 70% of prescriptions come from the community, half of patient starts occur in the community, and 150 new accounts were activated in 2025. They reiterated three ongoing Phase 3 trials—TEBE‑AM (enrollment on track to complete in 2026 with top‑line as early as H2 2026), ATOM (adjuvant uveal melanoma active in Europe with U.S. site activations planned in 2026), and PRISM‑MEL (IDMC selected the 160 μg dose, >200 sites activated, enrollment targeted to complete in 2027)—and framed the midterm opportunity as up to ~6× current demand (TEBE‑AM potentially addressing ~4,000 patients; ATOM ~1,000). Financially, they closed 2025 with approximately $864 million in cash and marketable securities (up >$40M YoY), reported sequential quarterly revenue growth of about 4–7% recently with moderation expected in 2026, and anticipate modest R&D expense increases and only incremental SG&A increases (historical SG&A run‑rate ~$40M/quarter) as they invest in pipeline and potential label expansion.Immunocore Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 385.76M | 297.57M | 247.98M | 197.39M | 144.23M | 27.04M |
| Gross Profit | 381.15M | 291.36M | 242.44M | 196.57M | 138.94M | 27.04M |
| EBITDA | 6.24M | 387.18K | -38.50M | -40.87M | -38.35M | -123.58M |
| Net Income | -18.82M | -26.42M | -40.81M | -43.75M | -43.46M | -133.45M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.07B | 1.01B | 472.44M | 526.76M | 407.28M |
| Cash, Cash Equivalents and Short-Term Investments | 844.90M | 864.15M | 820.38M | 350.27M | 402.47M | 321.06M |
| Total Debt | 435.68M | 436.69M | 432.72M | 66.50M | 81.45M | 86.16M |
| Total Liabilities | 678.42M | 686.24M | 648.79M | 180.55M | 187.86M | 175.76M |
| Stockholders Equity | 393.67M | 381.03M | 360.72M | 291.89M | 338.90M | 231.53M |
Cash Flow | ||||||
| Free Cash Flow | -30.72M | -11.20M | 20.89M | -1.97M | -51.41M | -144.49M |
| Operating Cash Flow | -24.90M | -7.97M | 26.06M | 2.33M | -49.21M | -143.11M |
| Investing Cash Flow | -21.83M | -12.16M | -355.13M | -4.29M | -2.20M | -1.28M |
| Financing Cash Flow | 10.47M | 9.20M | 343.88M | 27.18M | 145.44M | 288.19M |
Immunocore Holdings Technical Analysis
Positive
31.45
Price Trends
29.15
Positive
30.41
Positive
32.61
Negative
Market Momentum
0.26
Negative
63.40
Neutral
80.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMCR, the sentiment is Positive. The current price of 31.45 is above the 20-day moving average (MA) of 28.95, above the 50-day MA of 29.15, and below the 200-day MA of 32.61, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 80.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMCR.
Immunocore Holdings Risk Analysis
Immunocore Holdings disclosed 103 risk factors in its most recent earnings report. Immunocore Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immunocore Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $2.53B | -5.52 | 123.57% | ― | 75.92% | -569.22% | |
61 Neutral | $1.57B | -81.25 | -4.83% | ― | 23.64% | -29.23% | |
56 Neutral | $2.77B | -8.77 | -50.72% | ― | -88.54% | -58.13% | |
54 Neutral | $1.78B | 27.45 | 4.89% | ― | -2.20% | 77.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $6.51B | -12.58 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
IMCR
Immunocore Holdings
30.42
-0.96
-3.06%
BCRX
BioCryst
9.55
0.59
6.58%
CLDX
Celldex
37.44
17.09
83.98%
SRPT
Sarepta Therapeutics
17.02
-0.08
-0.47%
COGT
Cogent Biosciences
38.74
31.56
439.55%
Immunocore Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Immunocore Shareholders Back All Proposals at 2026 AGM
Positive
May 27, 2026
On May 27, 2026, Immunocore Holdings held its 2026 annual general meeting, where shareholders approved all ten resolutions, including the reappointment of directors Siddharth Kaul, William Pao, M.D., Ph.D., and Kristine Peterson, and an advisory e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.